LincR-PPP2R5C regulates IL-1β ubiquitination in macrophages and promotes airway inflammation and emphysema in a murine model of COPD
International Immunopharmacology · 2024
DOI: 10.1016/j.intimp.2024.112680 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2024. Verfasst von Min Wang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory and Critical Care Medicine, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China. Hauptthemen laut MEDLINE: Pulmonary Disease, Chronic Obstructive, Interleukin-1beta, Disease Models, Animal, Ubiquitination. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 52 Literaturangaben.
Themen: COPD
Abstract (Originalsprache)
Chronic obstructive pulmonary disease (COPD) is a common disease with high global morbidity and mortality. Macrophages release IL-1β and orchestrate airway inflammation in COPD. Previously, we explored the role of a new lncRNA, LincR-PPP2R5C, in regulating Th2 cells in asthma. Here, we established a murine model of COPD and explored the roles and mechanisms by which LincR-PPP2R5C regulates IL-1β in macrophages. LincR-PPP2R5C was highly expressed in pulmonary macrophages from COPD-like mice. LincR-PPP2R5C deficiency ameliorated emphysema and pulmonary inflammation, as characterized by reduced IL-1β in macrophages. Unexpectedly, in both lung tissues and macrophages, LincR-PPP2R5C deficiency decreased the expression of the IL-1β protein but not the IL-1β mRNA. Furthermore, we found that LincR-PPP2R5C deficiency increased the level of ubiquitinated IL-1β in macrophages, which was mediated by PP2A activity. Targeting PP2A with FTY720 decreased IL-1β and improved COPD. In conclusion, LincR-PPP2R5C regulates IL-1β ubiquitination by affecting PP2A activity in macrophages, contributing to the airway inflammation and emphysema in a murine model of COPD. PP2A and IL-1β ubiquitination in macrophages might be new therapeutic avenues for COPD therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Respiratory and Critical Care Medicine, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
- Department of Respiratory and Critical Care Medicine, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China. Electronic address: hm6114@163.com.
- Department of Respiratory and Critical Care Medicine, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China. Electronic address: jiningfei@163.com.
- Jiangsu Province Engineering Research Center of Antibody Drug, NHC Key Laboratory of Antibody Technique, Department of Immunology, Nanjing Medical University, Nanjing, China. Electronic address: mingshunzhang@njmu.edu.c…
Zitieren
APA
Wang, M., Zhu, M., Jia, X., Wu, J., Yuan, Q., Xu, T., Wang, Z., Huang, M., Ji, N., & Zhang, M. (2024). LincR-PPP2R5C regulates IL-1β ubiquitination in macrophages and promotes airway inflammation and emphysema in a murine model of COPD. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2024.112680
Vancouver
Wang M, Zhu M, Jia X, Wu J, Yuan Q, Xu T, et al. LincR-PPP2R5C regulates IL-1β ubiquitination in macrophages and promotes airway inflammation and emphysema in a murine model of COPD. International Immunopharmacology. 2024. doi:10.1016/j.intimp.2024.112680
BibTeX
@article{Wang2024,
author = {Wang, Min and Zhu, Manni and Jia, Xinyu and Wu, Jingjing and Yuan, Qi and Xu, Tingting and Wang, Zhengxia and Huang, Mao and Ji, Ningfei and Zhang, Mingshun},
title = {LincR-PPP2R5C regulates IL-1β ubiquitination in macrophages and promotes airway inflammation and emphysema in a murine model of COPD},
journal = {International Immunopharmacology},
year = {2024},
doi = {10.1016/j.intimp.2024.112680}
}
EUVIMED